Immunicum AB: inbjudan till företagspresentation
Pressmeddelande
21 september 2020
Immunicum AB: inbjudan till företagspresentation
Immunicum AB (publ; IMMU.ST) meddelar idag att företaget kommer att hålla en livesänd företagspresentation den 30 september 2020. Investerare, media och allmänheten välkomnas att delta.
Under evenemanget kommer VD Sven Rohmann, COO Sijme Zeilemaker och forskningschef Alex Karlsson-Parra att presentera en bolagsöversikt och prioriteringar för bolagets fortsatta utveckling.
Information om företagspresentationen
Datum: onsdagen den 30 september 2020
Tid: 18.00 - 19.30 CET
Presentationen kommer att webbsändas och kommer även att finnas tillgänglig i efterhand. Länken till webbsändningen finns här:
https://www.redeye.se/events/793598/live-strategy-update-immunicum
Frågor kan ställas före evenemanget genom att skicka ett e-postmeddelande till ir@immunicum.com eller via videochatten under webbsändningen.
Preliminär agenda:
18:00 - 18:15 Välkomnande
18:15 - 18:30 Ilixadencels potential och framtid
18:30 - 18:45 Prioriteringar för bolagets fortsatta utveckling
18:45 - 19:00 Långsiktigt uppdrag
19:00 - 19:30 Frågor och svar
Ett begränsat antal platser kommer att finnas tillgängliga på Redeyes kontor (Mäster Samuelsgatan 42, Stockholm, 10:e våningen) men på grund av riskerna förknippade med covid-19 rekommenderar bolaget alla att delta virtuellt. Om du planerar att delta personligen ber vi dig att skicka ett e-postmeddelande till info@immunicum.com med ditt fullständiga namn. Registreringen stänger när antalet platser är fulltecknade. Deltagare som känner sig sjuka eller riskerar att smittas förväntas avstå från att delta personligen. För uppdaterad information om rekommendationer angående covid-19, se www.folkhalsomyndigheten.se.
FÖR MER INFORMATION, VÄNLIGEN KONTAKTA:
Sven Rohmann, VD, Immunicum
Telefon: +46 8 732 84 00
E-post: info@immunicum.com
Sijme Zeilemaker, COO, Immunicum
Telefon: +46 8 732 84 00
E-post: info@immunicum.com
| Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier. Vårt mål är att bekämpa cancer genom att aktivera och stärka patientens eget immunförsvar, och därmed förbättra överlevnad och livskvalitet. Bolagets huvudprodukt ilixadencel, som består av pro-inflammatoriska allogena dendritiska celler, har potentialen att bli en grundkomponent i moderna kombinationsbehandlingar i flertalet solida tumörindikationer. Immunicum har utvärderat ilixadencel i flera olika kliniska studier, inklusive den nyligen avslutade explorativa fas II-studien MERECA inom njurcancer och bolaget går för närvarande mot klinisk utveckling i sen fas. Immunicum är grundat och baserat i Sverige och är noterat på Nasdaq Stockholm. www.immunicum.com |
Bilaga
För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.Om
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Följ GlobeNewswire by notified
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire by notified
Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release
Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10
Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of
RomReal 2023 Annual report including accounts and Audit statement19.4.2024 21:00:00 CEST | Press release
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments ANNUAL REPORT RomReal and Financial statements 2023Independent auditors report RomReal 2023
Landsbankinn hf.: Results of the 2024 AGM of Landsbankinn19.4.2024 20:48:08 CEST | Press release
The annual general meeting (AGM) of Landsbankinn, held on 19 April 2024, agreed to pay a dividend amounting to ISK 16,535 million to shareholders. The dividend is equivalent to 50% of 2023 profits. The dividend will be paid in two instalments, firstly on 24 April 2024 and secondly on 16 October 2024. As a result, total dividend paid by the Bank in 2013-2024 amounts to ISK 191.7 billion. At the AGM, held in Reykjastræti 6, Helga Björk Eiríksdóttir, Chairman of the Board of Directors, delivered the report from the Board for 2023. Lilja Björk Einarsdóttir, CEO, spoke of the Bank’s operation, strategy and activities in the past operating year. The annual financial statement for the past operating year was approved, as was the proposed Remuneration Policy and remuneration to Directors of the Board. The AGM elected the Auditor General (Ríkisendurskoðun) as auditor of Landsbankinn hf. for the 2024 operating year. The Auditor General, in accordance with an authorisation to outsource tasks, and
SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.19.4.2024 19:20:57 CEST | Press release
Reference is made to the announcement dated 31 January 2024, regarding Styrkás hf., a company 69.64% owned by SKEL fjárfestingafélag hf., signing a purchase agreement to acquire 100% of the shares in six subsidiaries of Máttarstólpi ehf. The purchase agreement was subject to the approval of the Competition Authority. The transaction was finalized today with payment of purchase price and delivering of shares in the following companies: - Stólpi Gámar ehf., id. 460121-1590, Klettagörðum 5, 104 Reykjavík: - Stólpi Smiðja ehf., id. 460121-1750, Klettagörðum 5, 104 Reykjavík; - Klettskjól ehf., id. 460121-0510, Klettagörðum 5, 104 Reykjavík; - Stólpi ehf., 460121-0430, Klettagörðum 5, 104 Reykjavík; - Tjónaþjónustan ehf., id. 460121-1670, Klettagörðum 5, 104 Reykjavík; - Alkul ehf., id. 491020-0830, Haukdælabraut 48, 113 Reykjavík. collectively referred to as "the sold companies". These companies will continue to be operated on a consolidated basis. The Enterprise value of the sold companie